As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
24 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:
24 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -793 -793 |
2%
2%
|
|
| EBIT (Operating Income) EBIT | -801 -801 |
3%
3%
|
|
| Net Profit | -767 -767 |
3%
3%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.
| Head office | Virgin Islands, British |
| CEO | Vladimir Coric |
| Employees | 256 |
| Founded | 2022 |
| Website | www.biohaven.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


